At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Leftover surgical tissue homogenization (other)
- How long the study runs
- Study runs about 123 months (dates as stated)
- About the drug or intervention
- Leftover surgical tissue homogenization — other: Leftover surgical tissue homogenization
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 800
- Started
- 2018-09-10
- Last checked
- 2025-05
Plain English Summary
What is this study?
- • Testing a new treatment for oncology
- • Clinical study - 800 participants
- • Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with oncology
Where?
- • London - Royal Marsden Hospital NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.
More detail
In order to establish the feasibility of homogenization as a potential companion diagnostic tool, our study aims to 1) evaluate how many surgical cases have left over tissue amenable to homogenization and 2) pilot homogenization across multiple tumour types. The molecular profile of the homogenate will be compared to that obtained from the diagnostic specimen using next generation sequencing techniques.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery.
- ✓Tissues for Research consent has been provided.
- ✓Patient age \>18yo.
- ✓Minimum of 1 gram of residual tumour remaining in leftover surgical tissue
- ✓Minimum of 1 gram of normal tissue present.
Who cannot take part
- ✗Advanced Practitioner in histological dissection deems tumour sample to be inadequate.
- ✗Leftover surgical tumour tissue greater than 20kg.
See the full criteria
Where Is This Study? (1 UK site)
Royal Marsden Hospital NHS Foundation Trust
London SW3 6JJ, United Kingdom
How to Get in Touch
Serena Vanzan
Sponsor contactCONTACT
Eleanor Carlyle
Sponsor contactCONTACT